Effects of Curcumin in Patients in Chronic Kidney Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03475017 |
Recruitment Status :
Active, not recruiting
First Posted : March 23, 2018
Last Update Posted : April 30, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Kidney Diseases | Dietary Supplement: Active Comparator: Supplement A Dietary Supplement: Placebo Comparator: Supplement B | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Health Services Research |
Official Title: | Effects of Curcumin Supplementation in Inflammation, Oxidative Stress and Intestinal Microbiota in Patients With Chronic Kidney Disease |
Actual Study Start Date : | February 22, 2018 |
Actual Primary Completion Date : | April 29, 2021 |
Estimated Study Completion Date : | December 30, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Supplement A
Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
|
Dietary Supplement: Active Comparator: Supplement A
The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
Other Name: Curcumin and piperine |
Placebo Comparator: Supplement B
Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
|
Dietary Supplement: Placebo Comparator: Supplement B
The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
Other Name: Placebo |
- Antioxidants and anti-inflammatory biomarkers [ Time Frame: 4 weeks ]Get blood samples to evaluate the supplementation effects in antioxidants biomarkers- nuclear receptor factor 2 (Nrf2), glutathioneperoxidase (GPx), heme oxygenase-1 (HO-1)
- Inflammatory biomarkers [ Time Frame: 4 weeks ]Get blood samples to evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappa B (NFkB), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of Chronic Kidney Disease
- Hemodialysis patients for more than 6 months
- Aged 18 years or older
- Must be able to swallow tablets
Exclusion Criteria:
- Patients pregnant
- Smokers
- Using antibiotics in the last 3 months
- Using antioxidant supplements in the last 3 months
- Usual intake of turmeric
- Usual intake Autoimmune
- Clinical diagnosis of infectious diseases
- Clinical diagnosis of Cancer
- Clinical diagnosis of AIDS

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03475017
Brazil | |
Denise Mafra | |
Rio de Janeiro, RJ, Brazil, 22260050 |
Responsible Party: | Denise Mafra, Doctor, Universidade Federal Fluminense |
ClinicalTrials.gov Identifier: | NCT03475017 |
Other Study ID Numbers: |
Denisemafra4 |
First Posted: | March 23, 2018 Key Record Dates |
Last Update Posted: | April 30, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Kidney Diseases Renal Insufficiency, Chronic Urologic Diseases Renal Insufficiency Curcumin Piperine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cytochrome P-450 Enzyme Inhibitors |